📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-08 09:33
0 analysed today
FollowTelegram
0
Today
151,433
All-time analysed
43,376
Positive
6,732
Negative
92,513
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
Fredun Pharma Unveils Pet-Care Acquisitions, Palghar Expansion & Target to Double Revenue
Fredun Pharmaceuticals issued a comprehensive business update for H1 FY27 outlining its pivot towards a 100% branded portfolio by 2029. The company has acquired a 26% stake in Goodman Vetcare at a ₹300 crore valuation and bought the Furlicks pet-wellness brand from USV/Wellbeing Nutrition. Additionally, a ~40,000 sq. ft. utility block at its Palghar facility is becoming operational in October 2026, alongside plans for another 50,000 sq. ft. expansion. Management has targeted doubling revenue and profitability over the next 3–4 years relative to its current operations (TTM revenue: ₹747 crore).
Confidence: HIGH
What changedFredun Pharma released an operational update detailing two pet-care acquisitions, facility additions at Palghar, and strategic revenue doubling targets.
Why it mattersThe transition from low-margin OEM manufacturing to high-margin branded pet care, diagnostics, and specialty wellness aims to expand operating margins beyond the current 14.7%.
Goodman Vetcare valuation: ₹300 croreGoodman Vetcare stake acquired: 26%Palghar capacity addition (October 2026): ~40,000 sq. ft.Planned Palghar expansion: 50,000 sq. ft.TTM Revenue base: ₹747 Cr
📅 Short termPositive sentiment from concrete expansion updates and pet-care acquisitions, though financial impact will reflect gradually over coming quarters.
📈 Long termTransformational if the company successfully pivots to a 100% branded model by 2029 and doubles revenue from the current ₹747 crore base while improving ROCE and margins.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risks in scaling retail veterinary stores and new brand SKUs
- High working capital/inventory intensity characteristic of pharma supply chains
Key Highlights
Acquired 26% stake in Goodman Vetcare at a valuation of ₹300 crore (implied acquisition equity value of ₹78 crore)
Acquired oral-strip brand Furlicks, planning to expand product portfolio from 6 SKUs to 22 SKUs over 6–9 months
Operationalizing ~40,000 sq. ft. utility block at Palghar in October 2026, with an additional 50,000 sq. ft. planned
Targeting a doubling of revenue and profitability over the next 3–4 years, shifting fully to branded business by 2029
Equity base expanded via 1.10 crore bonus shares in July 2026 and 3,61,599 warrant conversion shares in September 2026
👀 What to Watch
Track the operational rollout of the new Palghar utility block and monitor upcoming quarterly filings for revenue contributions from Goodman Vetcare and Furlicks.
Fredun Pharma Acquires 26% Stake in ₹300 Cr-Valued Goodman Vetcare
Fredun Pharmaceuticals has acquired a 26% stake in pet pharmacy chain Goodman Vetcare Private Limited, which is valued at ₹300 crore. Goodman Vetcare reported revenues of ₹23.6 crore in FY26 (up from ₹14.1 crore in FY24) and targets ₹40 crore in FY27 and ~₹100 crore by FY31. The acquisition provides Fredun with an omnichannel retail presence and forward integration for its animal healthcare and pet supplements business (Freossi). Goodman currently operates three stores across Mumbai and Navi Mumbai and plans to expand by adding at least eight new stores across three cities.
Confidence: HIGH
What changedFredun Pharmaceuticals acquired a 26% minority equity stake in Goodman Vetcare Private Limited.
Why it mattersProvides Fredun a direct retail and veterinary pharmacy distribution network to scale its high-margin Freossi pet care portfolio across India.
Goodman Vetcare valuation: ₹300 croreAcquired stake: 26%Goodman FY26 revenue: ₹23.6 croreGoodman FY31 revenue target: ~₹100 croreImplied stake value vs Fredun Net Worth: ~28% (₹78 cr / ₹278 cr)
📅 Short termPositive sentiment from strategic forward integration into pet retail, though cash consideration and funding method details remain key to monitor in the next quarterly filing.
📈 Long termSupports Fredun's stated strategy to pivot toward higher-margin pet wellness and direct consumer touchpoints, creating cross-selling synergies with its manufacturing arm.
⚠ Risk flags
- Retail execution risk in scaling from 3 stores to a pan-India footprint
- Cash outflow for the ~₹78 crore implied stake relative to existing debt of ₹222 crore
Key Highlights
Acquired a 26% stake in Goodman Vetcare, pegging the entity's valuation at ₹300 crore (implied deal value ~₹78 crore).
Goodman Vetcare grew revenue by 30% annually from ₹14.1 crore in FY24 to ₹23.6 crore in FY26.
Goodman targets revenue of ~₹40 crore by FY27, ~₹56 crore by FY28, and ~₹100 crore by FY31.
Expansion plans include opening at least 8 new stores across 3 cities and commissioning a new warehouse in H1.
👀 What to Watch
Track the integration timeline, rollout pace of the 8 planned stores outside Mumbai, and cash outflow/financing details for the 26% stake in upcoming financial disclosures.
Fredun Pharmaceuticals Equity Shares Admitted to Trade on NSE from August 17, 2026
Fredun Pharmaceuticals Limited has announced that its equity shares have been permitted to trade and admitted to dealings on the National Stock Exchange of India (NSE) effective August 17, 2026. The listing follows NSE Circular Ref. No. 1355/2026 dated August 14, 2026. The equity shares (Face Value Rs 10) will trade under the NSE symbol 'FREDUN' with ISIN INE194R01017. The company is already listed on BSE Limited, and this dual listing provides broader market access.
Confidence: HIGH
What changedFredun Pharmaceuticals' equity shares are now officially traded on the NSE in addition to the BSE.
Why it mattersListing on NSE significantly broadens investor access, improves stock liquidity, and enhances visibility among institutional and retail market participants.
Date of NSE trading commencement: August 17, 2026Face Value per share: Rs 10NSE Circular Date: August 14, 2026
📅 Short termMay see improved liquidity and increased daily trading turnover as access opens up to NSE-only trading accounts.
📈 Long termEnhances long-term capital market access and institutional visibility, though core business growth remains driven by product expansion and export scale.
Key Highlights
Trading on the National Stock Exchange (NSE) commenced on August 17, 2026
Assigned NSE trading symbol: FREDUN with ISIN INE194R01017
Listing approved pursuant to NSE Circular Ref. No. 1355/2026 dated August 14, 2026
Equity shares have a face value of Rs 10 per share
👀 What to Watch
Track trading volume and liquidity improvements across both exchanges, and monitor execution in upcoming quarterly financial results.
Fredun Pharma Q1 FY27 Revenue Up 90.4% to Rs 228.25 Cr, Guides 30-35% Blended Growth
Fredun Pharmaceuticals reported a 90.44% YoY surge in standalone Q1 FY27 total income to INR 228.25 crores, with EBITDA growing 92.90% to INR 32.78 crores and net profit expanding 94.63% to INR 13.17 crores. Management guided for a blended revenue CAGR of 30-35% over the next 3 to 4 years, driven by 35-45% growth in new-age consumer brands and 15-20% growth in legacy formulations. The Fredun GX generics business has scaled to 19 states with a current base of INR 100-110 crores, while pet care is targeting 40-50% growth supported by the commercial rollout of Wagr.in within 60-90 days.
Confidence: HIGH
What changedFredun Pharmaceuticals filed its Q1 FY27 earnings call transcript detailing operational updates, multi-year guidance, and business vertical roadmaps.
Why it mattersDemonstrates strong execution in pivoting toward higher-margin consumer-facing pet wellness, mobility, and generic distribution, supporting double-digit growth.
Q1 FY27 Total Income: INR 228.25 croresQ1 FY27 YoY Revenue Growth: 90.44%Q1 FY27 EBITDA: INR 32.78 croresQ1 FY27 PAT: INR 13.17 croresBlended 3-Year Growth Guidance: 30% to 35%Pet Care Growth Guidance: 40% to 50%
📅 Short termMarket sentiment remains supported by robust quarterly growth and management guidance, with focus shifting to the upcoming rollout milestones of Wagr.in.
📈 Long termStructural transformation from contract manufacturing to high-margin branded pet care and direct generics can re-rate profitability if working capital remains disciplined.
⚠ Risk flags
- High working capital requirements and inventory cycle
- API price volatility impacting generic margins
- Integration risks related to planned prospective acquisitions
Key Highlights
Q1 FY27 revenue rose 90.44% YoY to INR 228.25 crores, with net profit up 94.63% YoY to INR 13.17 crores.
EBITDA margins expanded 18 bps YoY to 14.36%, generating INR 32.78 crores in operating profit.
Management guided for 30-35% blended revenue growth over the next 3-4 years across existing and new lines.
Fredun GX expanded to 19 states with an expected annual run-rate base of INR 100-110 crores.
Pet care vertical guided to grow at 40-50% over the next 3 years from a base of INR 40-45 crores, targeting INR 18-24 crores from functional foods.
👀 What to Watch
Monitor the commercial scaling and beta completion of Wagr.in over the next 60-90 days, alongside quarterly operating margins and debt levels.
90% Revenue Growth: Fredun Pharmaceuticals Reports Strong Q1 FY27 Results
Fredun Pharmaceuticals reported a robust Q1 FY27 with total income jumping 90.44% YoY to ₹228.25 Cr. Net Profit nearly doubled, rising 94.63% YoY to ₹13.17 Cr, while EBITDA margins remained stable with a slight improvement of 18 bps to 14.36%. The company also completed a 2:1 bonus share allotment in July 2026, increasing its paid-up capital to 1.65 crore shares. This performance indicates strong momentum following a ₹639.12 Cr revenue year in FY26.
Confidence: HIGH
What changedFredun Pharmaceuticals has reported a significant acceleration in growth, nearly doubling its top and bottom lines in Q1 FY27 compared to the previous year.
Why it mattersThe results validate the company's strategy of diversifying into high-margin consumer-centric healthcare segments like pet care and mobility, reducing reliance on traditional OEM manufacturing.
Q1 FY27 Total Income: ₹228.25 CrYoY Revenue Growth: 90.44%Q1 FY27 Net Profit: ₹13.17 CrEBITDA Margin: 14.36%Q1 Revenue vs FY26 Revenue: 35.7%Bonus Issue Ratio: 2:1
📅 Short termThe stock is likely to react positively to the strong earnings surprise and the successful execution of the bonus issue.
📈 Long termThe company is structurally pivoting toward a branded healthcare model with multiple growth engines; sustained performance here could lead to further valuation re-rating.
⚠ Risk flags
- High debt-to-equity ratio (0.80)
- Vulnerability to API price volatility
- High inventory levels (191 days in FY24)
Key Highlights
Total Income surged 90.44% YoY to ₹228.25 Cr in Q1 FY27
Net Profit increased 94.63% YoY to ₹13.17 Cr from ₹6.77 Cr in Q1 FY26
EBITDA grew 92.90% YoY to ₹32.78 Cr with margins at 14.36%
Allotted 1.10 crore bonus equity shares in a 2:1 ratio on July 17, 2026
Q1 FY27 revenue accounts for approximately 35.7% of the total FY26 revenue of ₹639.12 Cr
👀 What to Watch
Investors should monitor if the company can maintain this high growth trajectory in the coming quarters and track the progress of the Palghar facility expansion. The shift toward high-margin segments like pet care (Freossi) and mobility (Brace On) is a key driver for margin expansion to watch.
Fredun Pharmaceuticals Approves Q1 FY27 Results; TTM Revenue at Rs 639 Cr
Fredun Pharmaceuticals approved its un-audited financial results for the quarter ended June 30, 2026, during a board meeting on August 5, 2026. The company is currently tracking a TTM revenue of Rs 639 Cr with an operating margin of 14.7%. Management continues to target a 25-30% growth rate by expanding the Freossi pet care brand and increasing own-brand exports, which currently account for 65% of export volume. Investors should evaluate the Q1 performance against the previous quarter's revenue of Rs 213 Cr to gauge if the growth trajectory is being maintained.
Confidence: MEDIUM
What changedThe company has finalized and approved its financial performance results for the first quarter of the 2026-27 fiscal year.
Why it mattersThis is the first quarterly update for FY27, providing a baseline to track the company's aggressive 25-30% growth target and its pivot toward high-margin pet care and mobility segments.
TTM Revenue: Rs 639 CrTTM PAT: Rs 38 CrOwn-brand export volume: 65%Trading window closure: July 01, 2026Debt-to-Equity: 0.80
📅 Short termThe stock price is likely to react to the specific revenue and margin growth figures in the detailed Q1 report relative to the Rs 213 Cr revenue recorded in Mar 2026.
📈 Long termStructural growth depends on the successful scaling of the Freossi pet care brand and the ability to mitigate API price volatility through high-margin branded products.
⚠ Risk flags
- API price volatility (potential 75% cost increase)
- High inventory levels (191 days in FY24)
- Debt-to-Equity ratio of 0.80
Key Highlights
Board meeting concluded on August 5, 2026, lasting 50 minutes from 10:30 a.m. to 11:20 a.m.
Approval of un-audited financial results for the first quarter ended June 30, 2026.
Trading window for insiders was closed for 35 days starting from July 1, 2026.
Statutory audit review for the period was conducted by M/s. R.H. Nisar & Co.
Company maintains a TTM PAT of Rs 38 Cr as per the latest available financial context.
👀 What to Watch
Review the detailed Q1 P&L statement to verify if the 14.7% operating margin is sustained and check for updates on the Palghar facility expansion progress.
Fredun Pharmaceuticals Approves Q1 FY27 Results; Board Meeting Concluded
Fredun Pharmaceuticals approved its un-audited financial results for the quarter ended June 30, 2026, in a board meeting held on August 5, 2026. The meeting was brief, lasting 50 minutes, and included the adoption of the Limited Review Report from the statutory auditors. This follows a strong FY26 where revenue reached Rs 635 Cr. Investors should now analyze the detailed results to see if the company is maintaining its 25-30% growth guidance and improving its 14.7% TTM operating margin.
Confidence: HIGH
What changedThe company has formally approved and released its financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersAs a high-growth pharma player with a P/E of 44.6, these results are critical to justify the current valuation and track the progress of its high-margin pet care and mobility divisions.
Quarter ended: 30th June, 2026Meeting duration: 50 minutesTTM Revenue: Rs 639 CrTTM PAT: Rs 38 Cr
📅 Short termThe stock price may react based on how the specific Q1 numbers compare to market expectations and previous quarter performance.
📈 Long termThe long-term outlook depends on the successful scaling of the Freossi pet care brand and the Brace On mobility division to reach the targeted 25-30% growth rate.
⚠ Risk flags
- API price volatility
- High inventory levels (191 days in FY24)
Key Highlights
Board approved un-audited financial results for the quarter ended June 30, 2026
Board meeting duration was 50 minutes, from 10:30 a.m. to 11:20 a.m.
Trading window for insiders has been closed since July 01, 2026
Limited Review Report issued by Statutory Auditor M/s. R.H. Nisar & Co
👀 What to Watch
Compare the Q1 FY27 revenue and PAT against the June 2025 quarter (Rs 120 Cr revenue, Rs 7 Cr PAT) to verify if the high-growth trajectory and margin expansion in pet care are sustaining.
